Calcium & Vitamin D on GLP-1: Biomarker Screening Guide

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists alter gastric motility and nutrient absorption, potentially affecting calcium and vitamin D status over time. Baseline screening before starting treatment helps establish individual risk and guides supplementation decisions.

PlexusDx supports precision wellness by connecting genetic predispositions in metabolic pathways with clinical biomarker data. Understanding your baseline nutrient status and metabolic profile helps providers tailor both GLP-1 dosing and supportive care for safer outcomes.

How GLP-1 Medications Influence Calcium and Vitamin D Metabolism

GLP-1 agonists slow gastric emptying and reduce overall food intake, decreasing dietary calcium and vitamin D exposure. Additionally, weight loss itself can alter bone turnover and mineral homeostasis, requiring provider monitoring to prevent nutrient depletion.

Studies show patients on long-term GLP-1 therapy experience changes in bone mineral density and markers of bone metabolism. Individual variation in these responses suggests baseline assessment and periodic rescreening are prudent clinical practices.

Baseline Biomarker Assessment Before GLP-1 Initiation

A comprehensive pre-treatment evaluation should include serum calcium, 25-hydroxyvitamin D, phosphate, magnesium, and alkaline phosphatase. These markers establish individual baseline status and guide supplementation strategy, helping providers anticipate potential deficiency risks.

Biomarker	Why It Matters on GLP-1	Typical Screening Interval
25-Hydroxyvitamin D	Reflects body stores; altered by reduced oral intake and malabsorption risk	Baseline, then 6–12 months
Total & Ionized Calcium	Monitors hypocalcemia risk; detects secondary hyperparathyroidism	Baseline, then 6–12 months
Parathyroid Hormone (PTH)	Elevates if calcium or vitamin D falls; indicates metabolic stress	Baseline and if calcium abnormal
Bone-Specific Alkaline Phosphatase	Marker of bone formation; helps track bone metabolism changes	Baseline and annually if indicated

Personalized Supplementation Strategy Based on Individual Status

Patients with low baseline vitamin D or calcium should begin supplementation before or concurrent with GLP-1 therapy. Dosing varies by individual deficit severity, absorption capacity, and concurrent medications—provider guidance is essential.

Some patients may benefit from divided dosing of calcium supplements, vitamin D3 forms matched to their metabolic needs, and periodic rescreening to assess efficacy. Genetic variation in vitamin D metabolism may also influence response to standard supplementation protocols.

Who Should Prioritize Nutrient Screening and When Provider Guidance Is Essential

Patients with prior bone loss, osteopenia, family history of osteoporosis, or malabsorptive conditions require early and frequent biomarker monitoring. Post-menopausal women and older adults face elevated bone fragility risk and should undergo baseline assessment before starting GLP-1 therapy.

Providers should reassess nutrient status at baseline, 6 months, and annually during GLP-1 treatment. Any symptoms of hypocalcemia, persistent fatigue, or bone pain warrant immediate biomarker evaluation and potential supplementation or medication adjustment.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test reveals predispositions in metabolic pathways that may influence how your body processes and utilizes calcium and vitamin D. Variants in genes controlling nutrient absorption and bone metabolism may help provide context for your individual baseline screening results and supplementation needs.

The Precision Peptide test does not predict exact nutrient deficiency but can identify genetic factors that increase risk for metabolic variation on GLP-1 therapy. This information should be interpreted with your qualified healthcare provider to inform whether you need more aggressive baseline screening or closer monitoring intervals.

Combining your genetic predisposition data with clinical biomarker assessment supports a more personalized conversation with your provider about nutrient support before and during GLP-1 treatment. This precision approach helps avoid one-size-fits-all supplementation and may reduce long-term bone and metabolic complications.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.